Compare ELOX & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELOX | TELA |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 41.3M |
| IPO Year | N/A | 2019 |
| Metric | ELOX | TELA |
|---|---|---|
| Price | $11.66 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 48.2K | ★ 85.2K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | N/A | $10.23 |
| Revenue Next Year | N/A | $14.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $10.00 | $0.50 |
| 52 Week High | $15.00 | $2.19 |
| Indicator | ELOX | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 38.06 | 51.00 |
| Support Level | N/A | $0.78 |
| Resistance Level | $15.00 | $0.94 |
| Average True Range (ATR) | 2.29 | 0.10 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 27.50 | 49.29 |
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.